The Louisiana lawsuit, which seeks to block telehealth prescribing and mailing of the abortion pill mifepristone, has major implications for abortion access nationwide.
A lower-court ruling had reinstated a Food and Drug Administration requirement that patients visit a health care provider in person to obtain mifepristone.
